BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23331666)

  • 21. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
    Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L
    Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
    Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
    J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
    Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
    Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
    JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
    Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
    J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
    Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
    Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma.
    Dixon PR; Au M; Hosni A; Perez-Ordonez B; Weinreb I; Xu W; Song Y; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
    Head Neck; 2016 Sep; 38(9):1347-53. PubMed ID: 27002481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of HPV in head and neck squamous cell carcinoma.
    Liang C; Marsit CJ; McClean MD; Nelson HH; Christensen BC; Haddad RI; Clark JR; Wein RO; Grillone GA; Houseman EA; Halec G; Waterboer T; Pawlita M; Krane JF; Kelsey KT
    Cancer Res; 2012 Oct; 72(19):5004-13. PubMed ID: 22991304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double positivity for HPV DNA/p16 in tonsillar and base of tongue cancer improves prognostication: Insights from a large population-based study.
    Garnaes E; Frederiksen K; Kiss K; Andersen L; Therkildsen MH; Franzmann MB; Specht L; Andersen E; Norrild B; Kjaer SK; von Buchwald C
    Int J Cancer; 2016 Dec; 139(11):2598-605. PubMed ID: 27537425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
    Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
    Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
    Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
    Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas.
    Baschnagel AM; Tonlaar N; Eskandari M; Kumar T; Williams L; Hanna A; Pruetz BL; Wilson GD
    J Oral Pathol Med; 2017 Mar; 46(3):208-213. PubMed ID: 27442811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WRAP53β, survivin and p16INK4a expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0-T3N0 glottic laryngeal cancer.
    Tiefenböck-Hansson K; Haapaniemi A; Farnebo L; Palmgren B; Tarkkanen J; Farnebo M; Munck-Wikland E; Mäkitie A; Garvin S; Roberg K
    Oncol Rep; 2017 Oct; 38(4):2062-2068. PubMed ID: 28849066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma.
    Ley J; Mehan P; Wildes TM; Thorstad W; Gay HA; Michel L; Nussenbaum B; Trinkaus K; Adkins D
    Oncology; 2013; 85(5):290-6. PubMed ID: 24217231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
    Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
    J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.